Company Overview
Snapshot
Founded in November 2009, Augma Biomaterials operates with 11–50 employees. The company gained significant recognition in January 2019 when its founder, Dr. Amos Yahav, was named an Edison Awards finalist for the Bond Apatite dental material technology.
Business overview
Augma Biomaterials specializes in the development, production, and marketing of synthetic bone substitutes for the dental market. Its core products, 3D Bond and Bond Apatite, are designed for bone regeneration in dental procedures, serving as scaffolds to fill, augment, or reconstruct bony defects in the oral and maxillofacial regions. The company's offerings are utilized by dentists and dental specialists globally, operating within the Health Tech & Life Sciences sector, specifically focusing on Biomaterials & Tissue Engineering.
Strategic signal
In January 2019, Augma Biomaterials' founder, Dr. Amos Yahav, was recognized as an Edison Awards finalist for his invention of Bond Apatite. This recognition highlights the innovative nature and proven efficacy of the company's dental material technology, which facilitates natural bone regeneration. The award signals strong validation of Augma Biomaterials' product development capabilities and its potential to impact the dental and maxillofacial surgery markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Augma Biomaterials' primary focus?
- Augma Biomaterials is dedicated to the development, production, and marketing of synthetic bone substitutes for the dental market, specifically for bone regeneration in oral and maxillofacial regions.
- What is Bond Apatite and its application?
- Bond Apatite is a cement-based osteoconductive composite developed by Augma Biomaterials, combining 3D Bond with hydroxyapatite granules. It is a synthetic bone substitute used for bone reconstruction in various dental applications, including filling, augmenting, and reconstructing defects in maxillofacial bones. The product is FDA cleared and CE approved.
- What recognition did Augma Biomaterials receive for its technology?
- In January 2019, Dr. Amos Yahav, founder of Augma Biomaterials, was selected as a finalist for the Edison Awards for his invention of Bond Apatite, a dental material technology that regenerates natural bone.
- Which markets does Augma Biomaterials serve?
- Augma Biomaterials serves global markets including Germany, the United Kingdom, Israel, France, Romania, South Africa, Hungary, Sweden, Turkey, Poland, and the United States.
- What is the function of 3D Bond?
- 3D Bond, a biphasic calcium sulfate product from Augma Biomaterials, functions as a scaffold for bone regeneration in dental procedures. It is intended to fill, augment, or reconstruct bony defects in the oral and maxillofacial region.